CRNX — Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: Total net revenue of $6.2 million, with $5.4 million from the U.S. launch of Palsonify and $800,000 from a licensing agreement with SKK in Japan.
• Full Year 2025 Revenue: Total revenue of $7.7 million.
• Cost of Product Revenue: $1.1 million in Q4, primarily due to commercial manufacturing capacity expansion and distribution costs.
• R&D Expenses: $85.1 million in Q4, down from $90.5 million in Q3, reflecting reduced startup costs for clinical studies.
• SG&A Expenses: $53.7 million in Q4, consistent with Q3.
• Cash Position: Ended 2025 with over $1 billion in cash and equivalents, bolstered by a $380 million public offering in January 2026.
• 2026 Operating Expense Guidance: Expected GAAP operating expenses between $606 million and $650 million, with non-GAAP expenses between $480 million and $520 million.

2. Strategic Updates and Business Highlights

• Palsonify Launch: Successfully launched as a preferred treatment for acromegaly, with over 200 enrollment forms received and 125 unique prescribers engaged.
• Pipeline Development: Progress on multiple late-stage candidates including Atezomelant for congenital adrenal hyperplasia (CAH) and Cushing's disease, and CRM 9682 for SST2-expressing tumors.
• Clinical Trials: Initiated Phase 3 studies for Atezomelant and reported promising Phase 2 data for ADCS.
• Market Access: Positive momentum with payers, securing formulary placements and navigating reimbursement processes effectively.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipated continued growth from Palsonify and ongoing clinical trials. The company believes existing cash reserves will fund operations into 2030.
• Market Strategy: Focus on establishing Palsonify as the new standard of care in acromegaly while expanding into CAH and other endocrine disorders.

4. Bad News, Challenges, or Points of Concern

• Launch Dynamics: The uptake of Palsonify may be lumpy due to the nature of orphan drug launches and external factors like weather impacting sales.
• Cost Management: While expenses were lower than expected, ongoing high R&D costs remain a concern as the company invests heavily in its pipeline.
• Market Competition: The competitive landscape in CAH and other endocrine therapies may pose challenges, especially as other treatments gain traction.

5. Notable Q&A Insights

• Palsonify Trends: Management refrained from providing specific quantitative trends for Palsonify's uptake but expressed optimism based on initial feedback from prescribers and patients.
• Payer Dynamics: No significant barriers to treatment were noted, with 50% of claims reimbursed and 50% using the QuickStart program.
• ADCS Study Design: The Phase 2/3 study for ADCS is designed to confirm dosing and efficacy, with a primary endpoint of normalizing urine free cortisol.
• Future Pipeline: Management emphasized the potential of CRM 9682 and its broad applicability, indicating a commitment to expanding beyond endocrinology if successful.

In summary, Crinetics Pharmaceuticals is positioned for growth with a strong financial foundation and a promising pipeline, although it faces challenges typical of new product launches in niche markets. The company remains focused on executing its strategic vision while navigating competitive pressures and operational hurdles.